Rheumatoid arthritis: developing pharmacological therapies
- 1 July 2002
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 11 (7) , 927-935
- https://doi.org/10.1517/13543784.11.7.927
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease that, despite recent advances in therapy, still results in significant morbidity, mortality and disability. The aetiology remains unknown and past therapies, although helpful for the majority of patients, have been suboptimal. The recent introduction of newer agents has changed the treatment paradigm of RA. COX-2 inhibitors, anti-TNF agents and interleukin-1 antagonists have allowed us to treat RA more effectively with relatively low risk of side effects. Investigations of other possible treatment pathways, such as inhibition of angiogenesis, may produce still better treatment and rapid unraveling of the immune system and how it relates to RA greatly enhances the opportunities for improved therapeutics in RA.Keywords
This publication has 49 references indexed in Scilit:
- Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugsThe American Journal of Medicine, 2001
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Preliminary results of early clinical trials with the fully human anti-TNFα monoclonal antibody D2E7Annals of the Rheumatic Diseases, 1999
- Effects of nabumetone compared with naproxen on platelet aggregation in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 1999
- Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs and selective COX-2 inhibitors, using sensitive microsomal and platelet assaysCanadian Journal of Physiology and Pharmacology, 1997
- Interleukin‐1β‐stimulated invasion of articular cartilage by rheumatoid synovial fibroblasts is inhibited by antibodies to specific integrin receptors and by collagenase inhibitorsArthritis & Rheumatism, 1997
- Inhibition of the production and effects of interleukins‐1 and tumor necrosis factor α in rheumatoid arthritisArthritis & Rheumatism, 1995
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993
- Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritisArthritis & Rheumatism, 1990
- The clinical significance of inhibition of renal prostaglandin synthesisKidney International, 1987